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INTRODUCTION
Inosine 5'-monophosphate dehydrogenase (IMPDH, EC 1.1.1.205) is the ratelimiting enzyme in de novo guanine nucleotide biosynthesis, catalyzing the NAD-dependent formation of X M P fiom IMP. This is the penultimate step in purine biosynthesis and the first step in this pathway specific to guanine nucleotide formation. Increased IMPDH activity was fist found m a screen of enzymatic activities in a series of rat hepatomas (1). This rise in activity correlated positively with the growth rate of the individual hepatomas (1). Subsequently, increased IMPDH expression and activity has been found in a variety of tumors and tumor cell lines (2) . The importance of IMPDH activity and guanine nucleotide levels in cellular proweration and maturation has been further substantiated by the findings that the inhibition of W D H activity w i t h the inhibitors mycophenolic acid or tiamfurin resulted in the cessation of cell replication and the induction of cellular differentiation in leukemia (3-6), breast tumor (7), and melanoma (8) cell lines. These effects could be circumvented by the restoration of guanine nucleotide levels through salvage of exogenously added guanosine. Regulation of IMPDH activity has also been shown to be important during T-lymphocyte activation during which W D H activity is increased ten-fold t x (9). Inhibitors of IMPDH inhibit T-cell activation (10) and are clinically immunosuppressive (1 1).
Additionally, IMPDH may be a target of action of the tumor suppressor p53. Decreased IMPDH activity and a suppressed phenotype was found in p53 temperature-inducible murine cells at the permissive temperature, with these effects being circumvented by the addition of exogenous purine bases (12) .
In humans, two distinct, highly similar (84% amino acid identity) IMPDH cDNAs termed type I and type II have been identified (13, 14) . In a comparison of the expression of these two mRNAs between normal lymphocytes and leukemic cell lines, it was found that type I IMPDH expression was similar in these cells, while type 11 IMPDH mRNA levels were specifically elevated in the tumor cell lines (15). Additionally, type II IMPDH mRNA levels were elevated when cells were stimulated to proliferate (16) and were depressed when cells were induced to differentiate (5-8, 16 ), while type I MPDH mRNA levels remained constant. Additionally, type II IMPDH mRNA levels are subject to end-product regulation (17). Increases in guanine ribonucleotide pools cause decreased type 11 MPDH mRNA levels, while depleted guanine ribonucleotide pools result in elevated type II IMPDH mRNA levels (17) .
Whereas W D H activity and gene expression have been shown to be regulated by diverse stimuli and biological events, no specific regulatory mechanisms have been identified except in the case of end-product regulation which occurs by a nuclear posttranscriptional event (17). To identi@ the regulatory mechanisms, elements, and components that govern type II IMPDH expression during cellular proliferation, transformation, Werenttiation, and in response to fluctuations in guanine ribonucleotide levels, we sought to isolate and characterize the gene that encodes this protein. Here we report the isolation, complete sequence and structure of the gene, and the characterization and regulation of the promoter. 
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MATERIALS AND METHODS
Gene isolation
We previously reported the isolation of two yeast artificial chromosome WAC) clones containing the fidl gene for type II IMI?DH (18) . One YAC (149C12) was used as a substrate to generate a PCR probe consisting largely of W D H intron sequences. Primers IMP2ut2 (5'-TCGGAGACACGCGGCGGTGT-3') and I M P 2 O M (5'-GTACCCAGGGAGAATGAGAA-3') amplified a 600-bp fkagment that was sequenced and found to contain a single 400-bp mtron.
This PCR ftagment was used as a probe to screen 5 x lo5 phage clones fiom a human peripheral blood genomic library (Promega, Madison, WI). Two clones, designated FFE-7 and FFE-9, were isolated and subjected to preliminary mapping experiments. FFE-9 was determined to be truncated for the 3' portion of the gene, while FFE-7 was deemed to contain the entire cod& sequence for type II IMPDH.
5' end analysis
To determine the starting point of type II W D H mRNA transcripts, a 1.1-kb NcoI fiagment was subcloned into pGEM-5 (Promega) and sequenced. The fkagment terminated at the translation initiation site and contained all of the previously reported UTR sequence (13) of the cDNA. The plasmid was linearized with AafII or EcoRI, the ends were blunted, and antisense riboprobes were prepared by using the Riboprobe System (Promega), T7 RNA polymerase, and 32P-UTP (NEN, Wihington, DE ) under the conditions specified by the manufacturer. The DNA template was destroyed with RNase-free DNase (Promega) and the probe purified by phenol extraction and ethanol precipitation. One x 1 Os cpm of riboprobe was hybridized to 2 pg of either human poIy(A)+ RNA or yeast tRNA in 80% formamide, 40 mM PIPES @H 6.7), 400 mM NaCl, and 1 mM EDTA, for 12 h at 45-C. Buffer was added to bring the reaction to 300 mM NaCl, 50 mM sodium acetate (PH 4.5), 5 mM ZnSO,, and 20 pg/d singIe stranded calfthymus DNA Three hundred units of S 1 nuclease were added, and digestion proceeded at 30°C for 1 h. The reaction was stopped by the addition of 0.25 volumes of 4 M ammoniUm acetate, 20 mM EDTA, and 40 p g / d tRNA. The reactions were ethanol-precipitated and resuspended in formamide loading dye and electrophoresed through a sequencing gel alongside a sequencing reaction. The gel was dried and exposed to autoradiography.
Sequence analysis and mRNA size determination
To determine the size of the coding portion of the IMf?DH gene, PCR was performed with primers complementary to sequences in the 5' UTR ( W 2 u t 2 ) and the 3' UTR (IMP2R2:
5'-CCGAGGAGGTGTGCTGGAT-3'). By this analysis, the coding portion of the gene was contained in 5.0 kbp of DNA and was therefore of suitably small size for complete sequence determination. Several strategies for sequencing were employed. Initially, 1.0 to 3.0-kbp restriction fragments were subcloned into pGEM (Promega) or pBluescript (Stratagene, La Jolla, CA) vectors. The inserts were subjected to nested deletion with exonuclease JII (19) and the resultant clones sequenced by using universal vector primers (T7, T3, and SP6). Subsequently, restriction sites identified in the initial experiments were used to clone smaller fragments and consequently to obtain the complete sequence of the gene. All sequencing was done by using the thermal-cycling-based femtomole sequencing kit (Promega) and 32P end-labeling of primers. Both strands of the gene were completely sequenced. To obtain an accurate estimate of the size of type I1 tMPDH mRNA species, we performed agarose gel electrophoresis of total human RNA fi-om
various tumor cell lines (HT-1080 fibrosarcoma, SK-MEL 13 1 melanoma, HL60 promyelocytic leukemia) in the presence of methylmercuric hydroxide with use of the buffer components as described (20) . IMPDH mRNA was detected by probing blots of these gels with a cDNA probe (13), and an estimate of the size was obtained by comparison to RNA size standards (GIBCO-BRC, Bethesda, MD).
Promoter determination and analysis
The 1,088-bp NcoI fiagment containing the 5' UTR and the putative promoter was rendered blunt-ended by treatment with the Klenow fragment of DNA polymerase I (Promega) and dNTPs. This fragment was subcloned into the Hindm site of plasmid pSV0-CAT, a promoterless plasmid containing the bacterial chloramphenicol acetyl transferase (CAT) gene, creating plasmid pNB-IMP-CAT. Constructs pNB AS-IMP-CAT, pNB ASD-IMP-CAT, and pNBASB-IMP-CAT were made by digesting pNB-IMP-CAT with ShI, SfuI and DraIII, or SfuI and BssHII, respectively, and then blunting the ends and recircularizing the plasmids by ligation.
The sequences at the boundaries of these deletions were verified by DNA sequencing with use of a type II lMPDH oligonucleotide primer. Two picomoles of each plasmid along with 2 pg of pSV-P-Galactosidase plasmid (Promega), was electroporated into either HT-1080 or SK-MEL 13 1 cells. After 2 d, RNA was isolated and analyzed by agarose-formaldehyde electrophoresis and Northern blotting as previously described (17) using CAT and P-galactosidase probes. mRNA levels were determined by densitometric analysis with a model CS-9 10 chromatogram scanner (Shimadzu Co., Kyoto, Japan).
DNA protein interactions in the promoter
Tlie 209-bp DraIII to NcoI fiagment containing sequences from -206 to +3 with respect to the translation initiation codon was labeled with 32P-dCTP and Klenow fiagment and was used as a target for gel-shift assays (21). Nuclear extracts were prepared fiom SK-MEL-13 1 cells as previously described (22) with published modifications (23). Reactions contained 12% glycerol, 12 mM HEPES (PH 7.9), 7.5 mM MgCl,, 60 mM KCl, 1 mM DTT, 70 pM EGTA, 300 p g / d BSA, 10 pg crude nuclear extract, 0.5 ng labeled probe, and various amounts of poly (WdC) (Sigma Chemical Co., St Louis, MO). Reactions were performed at 30°C for 20 m h and then were electrophoresed through a 4% polyacrylamide gels. The gel was then dried and exposed to autoradiography.
Golation and characterization of stable transfectants
Plasmids pNE3-IMP-CAT (10 pg) and pRSV-NE0 (3 pg 
RESULTS
Isolation and sequence of the type II: IMPDH gene
Through the use of an intron-containing probe, two genomic clones for type II IMPDH., FFE-7 and IFFE-9, were isolated fiom a genomic library. These clones were initially mapped by restriction digestion with enzymes that cleave the gene (Sac& Barn€& EcoRI, NcoI) and Southern blotting with use of 5' and 3' type II IMPDH cDNA probes. It was determined that FFE-9 was truncated in the 3' end, while FFE-7 contained the fidl gene. The observed hybridization patterns for clone FJ3-7 were identical to those obtained fiom blots of restricted human genomic DNA and restricted DNA fiom the two previously descriied (18) type II IMPDH YAC clones, 149C12 and 239B6. To determine the 5' end of the W D H transcript, a 1. l-kb NcoI fragment containing the previously reported 41-bp untranslated region (13) and over 1 kb of upstream sequence was subcloned and sequenced. Two antisense riboprobes initiating fiom the translation start codon but differing in their length were generated and used in S 1 nuclease protection experiments. The protected fragments (Fig. 1, Lanes 1,2 ) demonstrated some heterogeneity but revealed predominantly one major and one minor cap site for the transcript. The riboprobes protected no fi-agments when hybridized to yeast tRNA (Fig. 1, Lanes 3,4) . By running two sequencing reactions in parallel and taking into account a 5% slower mobility of RNA bands under these gel conditions, the major cap site was localized to nucleotide (nt) -102 and the minor cap site to nt -85 with respect to numbering of the A ofthe AUG codon as +l. There is no TATA box upstream of these cap sites, but there are four Sp 1 (24) binding sites starting at -170, -165, -152, 'and -140, as well as a binding site motif used by ATF (25), or in response to CAMP (26) or glucocorticoids (27). The region fi-om the minor start site at -85 to the Dram site at -206 is GC-rich (69 %) and contains 20 CpG dinucleotides.
Earlier estimates of the size of the m e II W D H gene established that the gene was smaller than 12.5 kb (18). To determine ifthe gene was small enough to be an effective substrate for PCR, two primers, one just 5' of the initiation codon and one just 3' of the translation termination codon., were used in an attempt to amplify the whole gene. These primers generated an approximately 5-kb PCR product with use of either clone FFE-7, or a previously described (Fig. 2) . The donor and acceptor intron splice sites (Table 1 ) all conform to proposed consensus sequences (28). The phases of the introns (29) are clustered with introns 2-5 of type 0, introns 6-9 of type 1, and introns 10-12 of type 2. A computer search through Genbank revealed the presence of two A hlike sequences in intron 5. Sequences from bases 2880-3040 and fi-om bases 3160-3320 are greater than 70% identical to previously reported A h sequences in Genbank. The data obtained fiom S 1 nuclease mapping and DNA sequence analysis predict an mRNA size for type I I IMPDH of 1,709 nts plus a poly(A) tail. To determine ifthis predicted size was in agreement with observed mRNA size, we performed agarose electrophoresis under conditions in which the mobility of RNA is proportional to its molecular weight (20) . With this system, it was determined that the size of the processed type I1 IMPDH mRNA transcript was between 1,800 and 1,900 nts (data not shown). for the gene, we made three deletions fiom this construct by using appropriately spaced restriction sites (Fig. 3) . With reference to the AUG as +I, the parental construct (PNB-IMP-CAT) contains sequences to -1084, the first deleted construct (PNBAS-IMP-CAT) contains sequences to -490, the second (PNBASD-IMP-CAT) contains sequences to -206, and the third @NBASB-IMP-CAT) contains sequences to -104. Equivalent amounts of these plasmids were cotransfected with p-P-Galactosidase into either €IT-1080 or SK-MEL-13 1 cells. These cells were analyzed 2 d later for CAT and P-galactosidase gene expression and relative transcription fiom the IMPDH promoter was determined. The deletions in the first two constructs had only minimal effect on transcriptional initiation fiom the IMPDH promoter in both cell types (Fig. 3) . The deletion from bp -206 to -104 in pNBASB-JMP-CAT resulted in substantial (96% of the parent construct) abrogatioii of transcriptional initiation, and those transcripts that were generated were of a highly To demonstrate specific DNA-protein interactions within this minimal promoter, we subjected a fiagment encompassing sequences fiom -206 to +3 to gel mobility shift analysis. As seen in Figure 4 , this labeled fiagment was nonspecifically bound by nuclear protein f?om SK-MEG13 1 cells in the absence of competitor DNA (Lane 2). When 3-30 pg of competitor poly(dI/dC) was added to the reactions (Lanes 3-6), a series of three complexes (labeled I, lI, and III) was observed. The sequence of the fiagment used in this assay (Fig. 4 (Fig. 5) .
As a preliminary investigation into the mechanism by which type II IMPDH gene expression is regulated by cellular proliferation rates, SK-MEL13 1 trmsfectmts were analyzed for CAT expression when growing in 111 medium supplemented with 15% fetal bovine serum and after a shift down to medium containing low (0.15%) serum. After 2 d of culture, cellular proliferation of the cells shiRed to low senrm had dropped to a rate such that cell numbers were 25% of the numbers attained by growth in fbll medium, As a consequence of this decreased cell replication, type II IMPDH mRNA levels were reduced to 40% of control and transcriptional initiation at the type II IMPDH promoter dropped to less than 30% of initiation at the promoter i n rapidly dividing cells. TATA-less promoters (36). Nuclear proteins specifically interact w i t h this region as evidenced by gel mobility shift assays, but whether these proteins are in fact Sp 1 or other transcription factors will require hrtlier analysis.
DISCUSSION
It has been previously reported that IMPDH may be a target for action of the p53 tumor suppressor (12). There is a p53 DNA binding motif starting at nt -371 of the IMPDH promoter, but, ,in in vitro studies, it has been determined that two of these motif& separated by 0-13 bp, are required for p53 binding (37 A 1.1-kb NcoI fiagment containing the previously reported 5' UTR plus additional upstream genomic sequences was subcloned into pGEM 5 (Promega). The plasmid was linearized with either AatII or EcoRI, the ends blunted, and riboprobes were synthesized as described in the Materials and Methods section. These probes were hybridized to either human poly(A)+ RNA or yeast tRNA arid then subjected to digestion w i t h S1 nuclease. The resultant products were then electrophoresed through denaturing polyacrylamide sequencing gels alongside two standard sequencing reactions. The left eight lanes shown are the two sequencing reactions. Labeled lanes are the protected fragments fiom hybridization of (1) AatII probe to human mRNA, (2) EcoRI probe to human mRNA, boundary. "lie size of the thirteenth exon is given by using the poly(A) addition site as its 3' boundary. Nuclear extracts were prepared fiom SK-MEL-13 1 cells as referenced in the Materials and Methods section. A 32P-labeled NcoUDraIII fiagment containing the minimal promoter was used as a probe to detect specific DNA protein interactions by using a gel mobility shift assay. Lanes are ( I ) probe alone; (2) probe and 10 pg ofnuclear extract; 3-6) probe, 10 pg nuclear extract, and 3, 9, 15, and 30 pg respectively of poly(dI/dC) competitor DNA. The F denotes free probe, while sequence of the fiagment used in this assay is given. The lowercase letters represent the minimal promoter up to the major cap site. Uppercase letters are expressed sequences. The four potential Sp 1 binding sites are underlined (the first two sites overlap), while a binding site for multiple transcription factors is in bold face. The major and minor cap sites are marked with an asterisk, and the translation initiation codon is italicized. 
